20 Eastbourne Terrace
About LivaNova PLCLivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. The company employs approximately 4,600 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business franchises: Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.A.), respectively.
CEO: Damien McDonald
CFO: Vivid Sehgal
Please click here for LivaNova job opportunities.
91 articles with LivaNova PLC
LivaNova Announces Settlement Agreement to Resolve Certain Litigation in the U.S. Related to the 3T Heater-Cooler Device
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced an agreement to settle approximately 75 percent of the previously disclosed litigation in the U.S. related to the Company’s 3T Heater-Cooler device.
Hebbelinck will lead global human resources, serve on the Executive Leadership Team and report to Chief Executive Officer Damien McDonald.
LivaNova to Present Autonomic Regulation Therapy Findings for Chronic Heart Failure Patients at the American College of Cardiology 68th Annual Scientific Session
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present three abstracts supporting the use of implantable neuromodulation technology to treat chronic heart failure during the American College of Cardiology 68th Annual Scientific Session (ACC 2019) from March 16-18 in New Orleans, USA.
LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter and full-year ended December 31, 2018.
LivaNova Announces Availability of Safety and Technical Information for Valve-in-Valve Procedures on Perceval Platform
New details provide insights on the suitability of the sutureless aortic valve for future transcatheter solutions
New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment
Recently published data reinforces the ability of Perceval to optimize the surgical approach to aortic valve replacement
The actor advocates for his son and others affected by epilepsy
LivaNova Comments on Proposed Decision Memo from the U.S. Centers for Medicare & Medicaid Services Regarding National Coverage Determination for VNS Therapy for Treatment-Resistant Depression
Final decision to be rendered by CMS in 90 days
LivaNova PLC today announced Thad Huston, Chief Financial Officer, will participate in discussions during the Piper Jaffray 30th Annual Healthcare Conference in New York and at the Berenberg European Conference 2018 in London.
LivaNova PLC today reported results for the quarter ended September 30, 2018.
LivaNova PLC today announced that Damien McDonald, Chief Executive Officer, will present at the Stifel 2018 Healthcare Conference on Tuesday, Nov. 13 in New York at 9:30 a.m. Eastern Standard Time.
The Company will release its third quarter 2018 results prior to the call.
LivaNova Launches International Pivotal Study Evaluating Use of Autonomic Regulation Therapy for Heart Failure
The study is an international, multi-center, randomized trial to evaluate the VITARIA System for the treatment of advanced heart failure.
Announcement comes as Company completes enrollment in PERSIST-AVR Trial for Perceval sutureless aortic valve
LivaNova VNS Therapy System for Drug-Resistant Epilepsy Could Save $77,000 Per Patient Over Five Years
Analysis finds overall cost savings far exceed system-related costs
LivaNova Launches Global Clinical Registry to Assess VNS Therapy Treatment for Drug-Resistant Epilepsy Patients
LivaNova PLC today announced the first implanted patient and official launch of a global registry to evaluate the use of LivaNova’s Vagus Nerve Stimulation Therapy® (VNS Therapy) System for patients with drug-resistant epilepsy
Company now focused on INTERLUDE CE Mark trial, building upon positive patient outcomes
LivaNova PLC reported results for the quarter ended June 30, 2018.
LivaNova PLC will host a conference call to discuss its second quarter 2018 results on Wednesday, Aug. 1, 2018 at 1 p.m. London time (8 a.m. Eastern Daylight Time).
LivaNova Receives FDA Clearance and Completes First Implant for its MEMO 4D Semi-rigid Mitral Annuloplasty Ring
MEMO 4D now offers a broader range of ring sizes from 24 to 42mm allowing an additional patient population with mitral regurgitation (“MR”) to be treated